Caspofungin (CFG) was tested in neutropenic and corticosteroid- immunosuppressed mice challenged with a lethal sinopulmonary inoculum of Rhizopus oryzae. Compared to untreated controls, CFG administered at 1 mg/kg of body weight/day significantly improved survival (54% versus 19%; P = 0.003) and reduced median R. oryzae fungal burden by 1.5 log10 for conidial equivalent DNA in neutropenic but not corticosteroid-immunosuppressed animals. CFG administered at 16 mg/kg/day was not significantly better than a saline control for treatment of invasive pulmonary mucormycosis (IPM) in either neutropenic or corticosteroid-immunosuppressed animals.
R. E. Lewis, K. Leventakos, G. Liao, D. P. Kontoyiannis (2011). Efficacy of Caspofungin in Neutropenic and Corticosteroid-Immunosuppressed Murine Models of Invasive Pulmonary Mucormycosis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55, 3584-3587 [10.1128/AAC.01812-10].
Efficacy of Caspofungin in Neutropenic and Corticosteroid-Immunosuppressed Murine Models of Invasive Pulmonary Mucormycosis
LEWIS, RUSSEL EDWARD;
2011
Abstract
Caspofungin (CFG) was tested in neutropenic and corticosteroid- immunosuppressed mice challenged with a lethal sinopulmonary inoculum of Rhizopus oryzae. Compared to untreated controls, CFG administered at 1 mg/kg of body weight/day significantly improved survival (54% versus 19%; P = 0.003) and reduced median R. oryzae fungal burden by 1.5 log10 for conidial equivalent DNA in neutropenic but not corticosteroid-immunosuppressed animals. CFG administered at 16 mg/kg/day was not significantly better than a saline control for treatment of invasive pulmonary mucormycosis (IPM) in either neutropenic or corticosteroid-immunosuppressed animals.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
